Elotuzumab + Iberdomide Post ABECMA
Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM
More Information
- Trial Status
- Not yet accepting
- Trial Phase
- Phase 1/2
- Enrollment
- 49 patients (estimated)
- Sponsors
- Dana-Farber Cancer Institute
- Collaborators
- Bristol Myers Squibb, Celgene Corporation, a wholly owned subsidiary of Bristol Myers Squibb
- Tags
- Monoclonal Antibody, SLAMF7, Post-CAR T
- Trial Type
- Treatment
- Last Update
- 2 weeks ago
- SparkCures ID
- 1968
- NCT Identifier
- NCT06518551
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.